title: Coordinated action of CK1 isoforms in canonical Wnt signaling.
abstract: Activation of the Wnt pathway promotes the progressive phosphorylation of coreceptor LRP5/6 (low-density lipoprotein receptor-related proteins 5 and 6), creating a phosphorylated motif that inhibits glycogen synthase kinase 3β (GSK-3β), which in turn stabilizes β-catenin, increasing the transcription of β-catenin target genes. Casein kinase 1 (CK1) kinase family members play a complex role in this pathway, either as inhibitors or as activators. In this report, we have dissected the roles of CK1 isoforms in the early steps of Wnt signaling. CK1ε is constitutively bound to LRP5/6 through its interaction with p120-catenin and E-cadherin or N-cadherin and is activated upon Wnt3a stimulation. CK1α also associates with the LRP5/6/p120-catenin complex but, differently from CK1ε, only after Wnt3a addition. Binding of CK1α is dependent on CK1ε and occurs in a complex with axin. The two protein kinases function sequentially: whereas CK1ε is required for early responses to Wnt3a stimulation, such as recruitment of Dishevelled 2 (Dvl-2), CK1α participates in the release of p120-catenin from the complex, which activates p120-catenin for further actions on this pathway. Another CK1, CK1γ, acts at an intermediate level, since it is not necessary for Dvl-2 recruitment but for LRP5/6 phosphorylation at Thr1479 and axin binding. Therefore, our results indicate that CK1 isoforms work coordinately to promote the full response to Wnt stimulus.
authors: Departament de Bioquímica i Biologia Molecular, CEB, Facultat de Medicina, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.
authors: Beatriz
authors: B
authors: Del Valle-Pérez
authors: Oriol
authors: O
authors: Arqués
authors: Meritxell
authors: M
authors: Vinyoles
authors: Antonio García
authors: AG
authors: de Herreros
authors: Mireia
authors: M
authors: Duñach
references: Cell Mol Life Sci. 2010 Aug;67(15):2551-62
references: 20229235
references: PLoS One. 2009;4(3):e4926
references: 19293931
references: J Biol Chem. 1999 Apr 16;274(16):10681-4
references: 10196136
references: J Cell Sci. 2010 Aug 1;123(Pt 15):2621-31
references: 20940130
references: Nat Rev Cancer. 2008 May;8(5):387-98
references: 18432252
references: Mol Cell Biol. 2007 Mar;27(5):1745-57
references: 17194753
references: Cell. 2002 Mar 22;108(6):837-47
references: 11955436
references: PLoS One. 2008;3(12):e4046
references: 19107203
references: Mol Cell Biol. 2009 Feb;29(4):953-64
references: 19075000
references: Adv Exp Med Biol. 1987;221:253-73
references: 2829583
references: J Cell Sci. 2016 Feb 15;129(4):873
references: 26905970
references: Dev Cell. 2009 Jul;17(1):9-26
references: 19619488
references: Genes Dev. 2006 Feb 15;20(4):399-410
references: 16481469
references: Cell. 2010 Dec 23;143(7):1136-48
references: 21183076
references: Cell Signal. 2005 Jun;17(6):675-89
references: 15722192
references: Nature. 2005 Dec 8;438(7069):867-72
references: 16341016
references: Development. 2004 Apr;131(8):1663-77
references: 15084453
references: Hybrid Hybridomics. 2004 Dec;23(6):343-51
references: 15684660
references: Mol Cell. 2001 Apr;7(4):801-9
references: 11336703
references: Oncogene. 2009 Aug 20;28(33):2999-3007
references: 19581931
references: J Biol Chem. 1999 Dec 17;274(51):36734-40
references: 10593980
references: PLoS One. 2008;3(12):e4080
references: 19114997
references: Mol Cell. 2003 Nov;12(5):1251-60
references: 14636582
references: J Biol Chem. 2004 Mar 26;279(13):13011-7
references: 14722104
references: Science. 2007 Jun 15;316(5831):1619-22
references: 17569865
references: Development. 2008 Jan;135(2):367-75
references: 18077588
references: Nature. 2005 Dec 8;438(7069):873-7
references: 16341017
references: PLoS Biol. 2003 Oct;1(1):E10
references: 14551908